Abstract
Progestational agents are often prescribed to prevent threatened miscarriage progressing to miscarriage, and subsequent miscarriages in recurrent pregnancy loss. Progestogens affect implantation, cytokine balance, natural killer cell activity, arachidonic acid release and myometrial contractility. A recent Cochrane review reported that progestogens were effective for treating threatened miscarriage with no harmful effects on mother or fetus. The results were not statistically different when vaginal progesterone was compared to placebo, (RR=0.47, 95% CI 0.17–1.30), whereas oral progestogen (dydrogesterone) was effective (RR=0.54, CI 0.35–0.84). The review concluded, that the small number of eligible studies, and the small number of the participants, limited the power of the metaanalysis. A later metaanalysis of five randomised controlled trials of threatened miscarriage comprised 660 patients. The results of 335 women who received dydrogesterone were compared to 325 women receiveing either placebo or bed rest. There was a 47% reduction in the odds ratio for miscarriage, (OR=0.47, CI 0.31–0.7). There was a 13% (44/335) miscarriage rate after dydrogesterone administration compared to 24% in control women. Recurrent miscarriage affects approximately 1% of women of child bearing age. A metaanalysis of progestational agents shows a 26% increase in the live birth rate. Again, dydrogesterone was associated with a more significant increase in the live birth rate than the other progestogens included in the metaanalysis.
References
1. Martel D, Monier MN, Roche D, Psychoyos A. Hormonal dependence of pinopode formation at the uterine luminal surface. Hum Reprod 1991;6:597–603.10.1093/oxfordjournals.humrep.a137386Search in Google Scholar
2. Psychoyos A. Uterine receptivity for nidation. Ann NY Acad Sci 1986;476:36–42.10.1111/j.1749-6632.1986.tb20920.xSearch in Google Scholar
3. Raghupathy R, Makhseed M, Azizieh F, Omu A, Gupta M, Farhat R. Cytokine production by maternal lymphocytes during normal human pregnancy and in unexplained recurrent spontaneous abortion. Hum Reprod 2000;15:713–8.10.1093/humrep/15.3.713Search in Google Scholar
4. Szekeres-Bartho J, Barakonyi A, Polgar B, Par G, Faust Z, Palkovics T, Szereday L. The role of gamma/delta T cells in progesterone-mediated immunomodulation during pregnancy: a review. Am J Reprod Immunol 1999;42:44–8.10.1111/j.1600-0897.1999.tb00464.xSearch in Google Scholar
5. Arck PC, Rücke M, Rose M, Szekeres-Bartho J, Douglas AJ, Pritsch M, Blois SM, Pincus MK, Bärenstrauch N, Dudenhausen JW, Nakamura K, Sheps S, Klapp BF. Early risk factors for miscarriage: a prospective cohort study in pregnant women. Reprod Biomed Online 2008;17:101–13.10.1016/S1472-6483(10)60300-8Search in Google Scholar
6. Roussev RG, Higgins NG, McIntyre JA. Phenotypic characterization of normal human placental mononuclear cells. J Reprod Immunol 1993;25:15–29.10.1016/0165-0378(93)90039-KSearch in Google Scholar
7. Chernyshov VP, Vodyanik MA, Pisareva SP. Lack of soluble TNF-receptors in women with recurrent spontaneous abortion and possibility for its correction. Am J Reprod Immunol 2005;54:284–91.10.1111/j.1600-0897.2005.00308.xSearch in Google Scholar PubMed
8. Dong YL, Gangula PR, Yallampalli C. Nitric oxide synthase isoforms in the rat uterus: differential regulation during pregnancy and labour. J Reprod Fertil 1996;107:249–54.10.1530/jrf.0.1070249Search in Google Scholar PubMed
9. Potdar N, Konje JC. The endocrinological basis of recurrent miscarriages. Curr Opin Obstet Gynecol 2005;17:424–8.10.1097/01.gco.0000175363.20094.bdSearch in Google Scholar PubMed
10. Arrowsmith S, Kendrick A, Wray S. Drugs acting on the pregnant uterus. Obstet Gynaecol Reprod Med 2010;20:241–7.10.1016/j.ogrm.2010.05.001Search in Google Scholar PubMed PubMed Central
11. Andronowska A, Chruściel M. Influence of estradiol-17β and progesterone on nitric oxide (NO) production in the porcine endometrium during first half of pregnancy. Reprod Biol 2008;8:43–55.10.1016/S1642-431X(12)60003-5Search in Google Scholar
12. Czajkowski K, Sienko J, Mogilinski M, Bros M, Szczecina R, Czajkowska A. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. Fertil Steril 2007;87:613–8.10.1016/j.fertnstert.2006.07.1506Search in Google Scholar
13. Csapo AI, Pulkkinen MO, Ruttner B, Sauvage JP, Wiest WG. The significance of the human corpus luteum in pregnancy maintenance. I. Preliminary studies. Am J Obstet Gynecol 1972;112:1061–7.10.1016/0002-9378(72)90181-0Search in Google Scholar
14. Babalioglu R, Varol FG, Ilhan R, Yalcin O, Cizmecioglu F. Progesterone profiles in luteal-phase defects associated with recurrent spontaneous abortions. J Assist Reprod Genet 1996;13:306–9.10.1007/BF02070143Search in Google Scholar
15. Li TC, Spuijbroek MD, Tuckerman E, Anstie B, Loxley M, Laird S. Endocrinological and endometrial factors in recurrent miscarriage. BJOG 2000;107:1471–9.10.1111/j.1471-0528.2000.tb11670.xSearch in Google Scholar
16. Stovall TG, Ling FW, Carson SA, Buster JE. Serum progesterone and uterine curettage in differential diagnosis of ectopic pregnancy. Fertil Steril 1992;57:456–7.10.1016/S0015-0282(16)54866-3Search in Google Scholar
17. Al-Sebai MA, Kingsland CR, Diver M, Hipkin L, McFadyen IR. The role of a single progesterone measurement in the diagnosis of early pregnancy failure and the prognosis of fetal viability. Br J Obstet Gynaecol 1995;102:364–9.10.1111/j.1471-0528.1995.tb11286.xSearch in Google Scholar
18. Abraham GE, Maroulis GB, Marshall JR. Evaluation of ovulation and corpus luteum function using measurements of plasma progesterone. Obstet Gynecol 1974;44:522–5.Search in Google Scholar
19. Philipp T, Philipp K, Reiner A, Beer F, Kalousek DK. Embryoscopic and cytogenetic analysis of 233 missed abortions: factors involved in the pathogenesis of developmental defects of early failed pregnancies. Hum Reprod 2003;18:1724–32.10.1093/humrep/deg309Search in Google Scholar
20. Carp HJ. Recurrent miscarriage: genetic factors and assessment of the embryo. Isr Med Assoc J 2008;10:229–31.Search in Google Scholar
21. Dhillon R, Hillman S, Morris R, McMullan D, Williams D, Coomarasamy A, Kilby M. Additional information from chromosomal microarray analysis (CMA) over conventional karyotyping when diagnosing chromosomal abnormalities in miscarriage: a systematic review and meta-analysis. Br J Obstet Gynaecol 2014;121:11–21.10.1111/1471-0528.12382Search in Google Scholar
22. Rubio C, Rodrigo L, Pérez-Cano I, Mercader A, Mateu E, Buendía P, Remohí J, Simón C, Pellicer A. FISH screening of aneuploidies in preimplantation embryos to improve IVF outcome. Reprod Biomed Online 2005;11:497–506.10.1016/S1472-6483(10)61146-7Search in Google Scholar
23. Wahabi HA, Fayed AA, Esmaeil SA, Al Zeidan RA. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev 2011;CD005943.10.1002/14651858.CD005943.pub3Search in Google Scholar
24. National Institute for Health and Care Excellence. Nice clinical Guideline No. 154 Ectopic Pregnancy and miscarriage. 2012. (http://www.nice.org.uk/guidance/cg154, accessed November 28, 2015).Search in Google Scholar
25. Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Progesterone support of the luteal phase and in the first trimester. 2013. (www.ranzcog.edu.au, accessed November 28, 2015).Search in Google Scholar
26. Yassaee F, Shekarriz-Foumani R, Afsari S, Fallahian M. The effect of progesterone suppositories on threatened abortion: a randomized clinical trial. J Reprod Infertil 2014;15:147–51.Search in Google Scholar
27. Carp HJ. A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gynecol Endocrinol 2012;28:983–90.10.3109/09513590.2012.702875Search in Google Scholar
28. Sauebrei EE. Early pregnancy: pre-embrionic and embrionic periods. In: Sauebrei EE, Nguyen KT, Nolan RL, editors. A practical guide to ultrasound in obstetrics and gynecology. Philadelphia, PA: Lippincott-Raven Publishers, 1998;122–31.Search in Google Scholar
29. Bennett GL, Bromley B, Lieberman E, Benacerraf BR. Subchorionic hemorrhage in first-trimester pregnancies: prediction of pregnancy outcome with sonography. Radiology 1996;200:803–6.10.1148/radiology.200.3.8756935Search in Google Scholar
30. Tuuli MG, Norman SM, Odibo AO, Macones GA, Cahill AG. Perinatal outcomes in women with subchorionic hematoma: a systematic review and meta-analysis. Obstet Gynecol 2011;117:1205–12.10.1097/AOG.0b013e31821568deSearch in Google Scholar
31. Pelinescu-Onciul D, Radulescu-Botica R, Steriu M, Cheles C, Varlas V. Terapia cu progesteron micronizat a hematoameloreciduale. Infomedica 1999;2S:32–5.Search in Google Scholar
32. Pelinescu-Onciul D. Subchorionic hemorrhage treatment with dydrogesterone. Gynecol Endocrinol 2007;23(Suppl 1):77–81.10.1080/09513590701584741Search in Google Scholar
33. Stirrat GM. Recurrent miscarriage. Lancet 1990;336:673–5.10.1016/0140-6736(90)92159-FSearch in Google Scholar
34. Daya S. Efficacy of progesterone support for pregnancy in women with recurrent miscarriage. A meta-analysis of controlled trials. Br J Obstet Gynaecol 1989;96:275–80.10.1111/j.1471-0528.1989.tb02386.xSearch in Google Scholar PubMed
35. Oates-Whitehead RM, Haas DM, Carrier JA. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 2003;CD003511.10.1002/14651858.CD003511Search in Google Scholar PubMed
36. El-Zibdeh MY. Dydrogesterone in the reduction of recurrent spontaneous abortion. J Steroid Biochem Mol Biol 2005;97:431–4.10.1016/j.jsbmb.2005.08.007Search in Google Scholar PubMed
37. Kumar A, Begum N, Prasad S, Aggarwal S, Sharma S. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial. Fertil Steril 2014;102:1357–63.10.1016/j.fertnstert.2014.07.1251Search in Google Scholar PubMed
38. Freedman RS. Progesterone defficiency in pregnancy. S Afr Med J 1970;44:72–6.10.7326/0003-4819-72-5-802_1Search in Google Scholar
39. Coomarasamy A, Williams H, Truchanowicz E, Seed PT, Small R, Quenby S, Gupta P, Dawood F, Koot YE, Bender Atik R, Bloemenkamp KW, Brady R, Briley AL, Cavallaro R, Cheong YC, Chu JJ, Eapen A, Ewies A, Hoek A, Kaaijk EM, Koks CA, Li TC, MacLean M, Mol BW, Moore J, Ross JA, Sharpe L, Stewart J, Vaithilingam N, Farquharson RG, Kilby MD, Khalaf Y, Goddijn M, Regan L, Rai R. A Randomized Trial of Progesterone in Women with Recurrent Miscarriages. N Engl J Med. 2015;373:2141–8.10.1056/NEJMoa1504927Search in Google Scholar PubMed
40. Whalen RE, Peck CK, LoPiccolo J. Virilization of female rats by prenatally administered progestin. Endocrinology 1996;78:965–70.10.1210/endo-78-5-965Search in Google Scholar PubMed
41. Carmichael SL, Shaw GM, Laurent C, Croughan MS, Olney RS, Lammer EJ. Maternal progestin intake and risk of hypospadias. Arch Ped Adol Med 2005;159:957–62.10.1001/archpedi.159.10.957Search in Google Scholar PubMed
42. Bartholomeusz RK, Bruce NW. Effects of maternal progesterone supplementation on fetal, placental and corpus luteal weights in the rat. Biol Reprod 1976;15:84–9.10.1095/biolreprod15.1.84Search in Google Scholar PubMed
43. Michaelis J, Michaelis H, Glück E, Koller S. Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations. Teratol 1983;27:57–64.10.1002/tera.1420270109Search in Google Scholar PubMed
44. Zaqout M, Aslem E, Abuqamar M, Abughazza O, Panzer J, De Wolf D. The impact of oral intake of dydrogesterone on fetal heart development during early pregnancy. Pediatr Cardiol 2015;36:1483–8.10.1007/s00246-015-1190-9Search in Google Scholar PubMed
45. Tikkanen J, Heinonen OP. Congenital heart disease in the offspring and maternal habits and home exposures during pregnancy. Teratol 1992;46:447–54.10.1002/tera.1420460509Search in Google Scholar PubMed
46. Shi H, Yang S, Liu Y, Huang P, Lin N, Sun X, Yu R, Zhang Y, Qin Y, Wang L. Study on environmental causes and SNPs of MTHFR, MS and CBS genes related to congenital heart disease. PLoS One 2015;10:e0128646.10.1371/journal.pone.0128646Search in Google Scholar PubMed PubMed Central
47. Eggimann UH, Thürig E, Moser H, Bossi E [Threatened abortion: patient characteristics, treatment results and consequences for the child]. Schweiz Med Wochenschr 1979;109:288–92. [Article in German].Search in Google Scholar
48. Queisser-Luft A. Dydrogesterone use during pregnancy: overview of birth defects reported since 1977. Early Hum Dev 2009;85:375–7.10.1016/j.earlhumdev.2008.12.016Search in Google Scholar PubMed
49. Di Renzo GC, Matteia A, Gojnic M, Gerli S. Progesterone and pregnancy. Curr Op Obstet Gynecol 2005;17:598–600.10.1097/01.gco.0000191899.84567.4dSearch in Google Scholar PubMed
50. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins. Maturitas 2008;61:171–80.10.1016/j.maturitas.2003.09.014Search in Google Scholar PubMed
©2016 Walter de Gruyter GmbH, Berlin/Boston
